In Brief: Roussel Uclaf's Anandron
Executive Summary
Roussel Uclaf's Anandron: Is "approvable" March 7 for use in combination with surgical castration for treatment of metastatic prostate cancer. Anandron (nilutamide) was recommended for approval by an FDA advisory committee Feb. 24 ("The Pink Sheet" Feb. 27, p. 13)...